A protein that targets the effects of a faulty gene could offer the first treatment targeting the major genetic cause of pulmonary arterial hypertension, according to research funded by the British Heart Foundation (BHF) and carried out at the University of Cambridge.
A protein that targets the effects of a faulty gene could offer the first treatment targeting the major genetic cause of pulmonary arterial hypertension, according to research funded by the British Heart Foundation (BHF) and carried out at the University of Cambridge.
The next step for our research is studies in people with pulmonary arterial hypertension – first, safety testing to ensure the compound can be given to people. But we’re confident of passing this phase because BMP9 exists naturally in the body. We’re just giving patients more of it.
Nick Morrell
Genetic evidence dating back to 2000, from research the BHF helped to fund, indicated that the absence or reduced activity of a particular protein, bone morophogenetic protein type II receptor (BMPR-II), leads to pulmonary arterial hypertension. BMPR-II is important to the normal function of the blood vessels of the lungs. Pulmonary arterial hypertension is thought to affect around 6,500 people in the UK.
In research published in Nature Medicine, BHF Professor of Cardiopulmonary Medicine Nick Morrell and colleagues report the first use a protein, called BMP9, to reverse the effects of reduced activity of BMPR-II and to reverse the disease itself. The study was conducted in mice and rats, but also using cells from patients with pulmonary arterial hypertension.
Pulmonary arterial hypertension is a chronic and debilitating disease that affects the blood vessels in the lungs, leading to heart failure, and leaves sufferers feeling breathless and exhausted. Current treatments only target the symptoms and prognosis remains poor. The only effective cure is a lung, or heart and lung, transplant, which has associated risks and complications.
Once diagnosed with pulmonary arterial hypertension, a person has a 30 per cent chance of dying within three years and the condition affects more women than men. Researchers speculate that this gender disparity is caused by pregnancy triggering the disease in genetically susceptible women or that oestrogen can affect the function of BMPR-II.
The Cambridge team, with contributions from researchers at the University of Lincoln, Switzerland and the US, searched for a BMP protein that could enhance the function of BMPR-II to target the condition. The researchers firstly trialled different BMP proteins on lung blood vessel cells grown in a dish. This process showed BMP9 to be most selective, and therefore less likely to have negative effects on other cells.
This study used the first animal model, a mouse, which closely mimics the human genetic form of the disease. Ultimately though, the team showed that BMP9 treatment reversed pulmonary arterial hypertension in three separate mouse and rat models. They found that the treatment works in mice with both the genetic from of the disease, and in acquired forms of pulmonary arterial hypertension, where the cause is unknown.
Professor Morrell, from the Department of Medicine at the University of Cambridge, and Director of the BHF Cambridge Centre for Cardiovascular Research Excellence, said: “The next step for our research is studies in people with pulmonary arterial hypertension – first, safety testing to ensure the compound can be given to people. But we’re confident of passing this phase because BMP9 exists naturally in the body. We’re just giving patients more of it.”
The study has been welcome by the BHF, which funded the research. Professor Jeremy Pearson, Associated Medical Director, said: “We’re very excited by these results. This condition is horrible and an effective treatment that prevents the need for a transplant would be a game-changer.
“Clinical trials of the treatment in patients are still needed but these findings, from years of research supported by the BHF, offer real promise of a cure.”
"A treatment can’t come soon enough."
Kath Graham, 53 years old from Stevenage, was collapsing almost daily and confined to a wheelchair because of the severity of her pulmonary arterial hypertension and the treatments for it, until she had a heart and lung transplant in September 2013. Before her transplant, she needed to have a continuous infusion of intravenous (IV) medications.
“It meant having a small pump, which I carried around on an elastic waistband. I had to prepare an infusion in a sterile environment twice a day and put that into a syringe attached to the pump which then infused the drug continuously through a permanent line fitted by the hospital.
“I didn’t have a choice because at that stage I was collapsing every few days. Just climbing out of bed, I would collapse and pass out so I had a sort of love/hate relationship with it. I knew the IV drugs were helping to keep me well until I could get a transplant but they also made me quite sick.
“I’m so grateful for my transplant but, it would have been so much better if I could have taken a medicine that worked and didn’t have the same side effects. The research happening at Cambridge, supported by the BHF, gives me some hope for all my friends who have pulmonary arterial hypertension. A treatment can’t come soon enough.”
Adapted from a press release from the British Heart Foundation.
Reference
Lu Long et al. Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension. Nature Medicine; 15 June 2015
The text in this work is licensed under a Creative Commons Attribution 4.0 International License. For image use please see separate credits above.
